Search

Your search keyword '"Cordonnier, Catherine"' showing total 800 results
Start Over Author "Cordonnier, Catherine"
800 results on '"Cordonnier, Catherine"'

1. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)

Author

Cesaro, Simone, Mikulska, Malgorzata, Hirsch, Hans H., Styczynski, Jan, Meylan, Sylvain, Cordonnier, Catherine, Navarro, Davide, von Lilienfeld-Toal, Marie, Mehra, Varun, Marchesi, Francesco, Besson, Caroline, Masculano, Raul Cordoba, Beutel, Gernot, Einsele, Herman, Maertens, Johan, de la Camara, Rafael, Ljungman, Per, and Pagano, Livio

Published
2023
Full Text
View/download PDF

2. Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT

Author

Styczynski, Jan, Tridello, Gloria, Koster, Linda, Knelange, Nina, Wendel, Lotus, van Biezen, Anja, van der Werf, Steffie, Mikulska, Malgorzata, Gil, Lidia, Cordonnier, Catherine, Ljungman, Per, Averbuch, Diana, Cesaro, Simone, Baldomero, Helen, Chabannon, Christian, Corbacioglu, Selim, Dolstra, Harry, Glass, Bertram, Greco, Raffaella, Kröger, Nicolaus, de Latour, Régis Peffault, Mohty, Mohamad, Neven, Benedicte, Peric, Zinaida, Snowden, John A., Sureda, Anna, Yakoub-Agha, Ibrahim, and de la Camara, Rafael

Published
2023
Full Text
View/download PDF

3. Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022

Author

Aerts, Robina, Mehra, Varun, Groll, Andreas H, Martino, Rodrigo, Lagrou, Katrien, Robin, Christine, Perruccio, Katia, Blijlevens, Nicole, Nucci, Marcio, Slavin, Monica, Bretagne, Stéphane, and Cordonnier, Catherine

Published
2024
Full Text
View/download PDF

4. When to change treatment of acute invasive aspergillosis: an expert viewpoint

Author

Slavin, Monica A, Chen, Yee-Chun, Cordonnier, Catherine, Cornely, Oliver A, Cuenca-Estrella, Manuel, Donnelly, J Peter, Groll, Andreas H, Lortholary, Olivier, Marty, Francisco M, Nucci, Marcio, Rex, John H, Rijnders, Bart JA, Thompson, George R, Verweij, Paul E, White, P Lewis, Hargreaves, Ruth, Harvey, Emma, and Maertens, Johan A

Subjects
Infectious Diseases, Clinical Trials and Supportive Activities, Rare Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Antifungal Agents, Aspergillosis, Bronchoalveolar Lavage Fluid, Humans, Immunocompromised Host, Invasive Fungal Infections, Invasive Pulmonary Aspergillosis, Mannans, Microbiology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences
Abstract

Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.

Published
2021

5. Endemic or regionally limited bacterial and viral infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review

Author

Muhsen, Ibrahim N, Galeano, Sebastian, Niederwieser, Dietger, Koh, Mickey B C, Ljungman, Per, Machado, Clarisse M, Kharfan-Dabaja, Mohamed A, de la Camara, Rafael, Kodera, Yoshihisa, Szer, Jeff, Rasheed, Walid, Cesaro, Simone, Hashmi, Shahrukh K, Seber, Adriana, Atsuta, Yoshiko, Saleh, Mostafa F Mohammed, Srivastava, Alok, Styczynski, Jan, Alrajhi, Abdulrahman, Almaghrabi, Reem, Abid, Muhammad Bilal, Chemaly, Roy F, Gergis, Usama, Brissot, Eolia, El Fakih, Riad, Riches, Marcie, Mikulska, Malgorzata, Worel, Nina, Weisdorf, Daniel, Greinix, Hildegard, Cordonnier, Catherine, and Aljurf, Mahmoud

Published
2023
Full Text
View/download PDF

6. Endemic or regionally limited parasitic and fungal infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review

Author

Muhsen, Ibrahim N, Galeano, Sebastian, Niederwieser, Dietger, Koh, Mickey B C, Ljungman, Per, Machado, Clarisse M, Kharfan-Dabaja, Mohamed A, de la Camara, Rafael, Kodera, Yoshihisa, Szer, Jeff, Rasheed, Walid, Cesaro, Simone, Hashmi, Shahrukh K, Seber, Adriana, Atsuta, Yoshiko, Saleh, Mostafa F Mohammed, Srivastava, Alok, Styczynski, Jan, Alrajhi, Abdulrahman, Almaghrabi, Reem, Abid, Muhammad Bilal, Chemaly, Roy F, Gergis, Usama, Brissot, Eolia, El Fakih, Riad, Riches, Marcie, Mikulska, Malgorzata, Worel, Nina, Weisdorf, Daniel, Greinix, Hildegard, Cordonnier, Catherine, and Aljurf, Mahmoud

Published
2023
Full Text
View/download PDF

7. Polymerase Chain Reaction on Respiratory Tract Specimens of Immunocompromised Patients to Diagnose Pneumocystis Pneumonia: A Systematic Review and Meta-analysis

Author

Brown, Lottie, primary, Rautemaa-Richardson, Riina, additional, Mengoli, Carlo, additional, Alanio, Alexandre, additional, Barnes, Rosemary A, additional, Bretagne, Stéphane, additional, Chen, Sharon C A, additional, Cordonnier, Catherine, additional, Donnelly, J Peter, additional, Heinz, Werner J, additional, Jones, Brian, additional, Klingspor, Lena, additional, Loeffler, Juergen, additional, Rogers, Thomas R, additional, Rowbotham, Eleanor, additional, White, P Lewis, additional, and Cruciani, Mario, additional

Published
2024
Full Text
View/download PDF

8. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)

Author

Cesaro, Simone, Ljungman, Per, Mikulska, Malgorzata, Hirsch, Hans H., von Lilienfeld-Toal, Marie, Cordonnier, Catherine, Meylan, Sylvain, Mehra, Varun, Styczynski, Jan, Marchesi, Francesco, Besson, Caroline, Baldanti, Fausto, Masculano, Raul Cordoba, Beutel, Gernot, Einsele, Herman, Azoulay, Elie, Maertens, Johan, de la Camara, Rafael, and Pagano, Livio

Published
2022
Full Text
View/download PDF

9. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia

Author

Greinix, Hildegard, Maertens, Johan, De Greef, Julien, Slavin, Monica, Spriet, Isabel, Hubacek, Petr, Bergeron, Anne, Cordonnier, Catherine, Kanerva, Jukka, Herbrecht, Raoul, Herrmann, Jean-Louis, Lanternier, Fanny, Bondeelle, Louise, Robin, Christine, Einsele, Hermann, Lehrnbecher, Thomas, Groll, Andreas, Maschmeyer, Georg, Lange, Christoph, von Lilienfeld-Toal, Marie, Pana, Dorothea, Roilides, Emmanuel, Kassa, Csaba, Averbuch, Diana, Engelhard, Dan, Cesaro, Simone, Mikulska, Malgorzata, Pagano, Livio, Castagnola, Elio, Compagno, Francesca, Goletti, Delia, Mesini, Alessio, Donnelly, Peter J, Styczynski, Jan, Botelho de Sousa, Aida, Aljurf, Mahmoud, de la Camara, Rafael, Navarro, David, Rovira, Montserrat, Franquet, Tomas, Garcia-Vidal, Carol, Ljungman, Per, Paukssen, Karlis, Ammann, Roland, Lamoth, Frédéric, Hirsch, Hans, Ritz, Nicole, Akova, Murat, Ceesay, Mansour, Warris, Adilia, Chemaly, Roy, and Donnelly, J Peter

Published
2022
Full Text
View/download PDF

11. Pneumocystis Pneumonia After Allogeneic Hematopoietic Cell Transplantation: A Case-Control Study on Epidemiology and Risk Factors on Behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Author

Robin, Christine, Cordonnier, Catherine, Tridello, Gloria, Knelange, Nina, Xhaard, Alienor, Chantepie, Sylvain, Tanguy-Schmidt, Aline, Schouten, Harry C., Yeshurun, Moshe, Rocha, Vanderson, Srour, Micha, Kröger, Nicolaus, Ledoux, Marie-Pierre, Dalgaard, Jakob, Thiebaut, Anne, Giardino, Stefano, Calore, Elisabetta, Zuckerman, Tsila, Groll, Andreas H., Raida, Ludek, Avcin, Simona, Vicent, Marta Gonzalez, Kaare, Ain, Drozd-Sokolowska, Joanna, Turlure, Pascal, Bretagne, Stéphane, Mikulska, Malgorzata, Camara, Rafael de la, Cesaro, Simone, and Styczynski, Jan

Published
2024
Full Text
View/download PDF

12. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee

Author

Algwaiz, Ghada, Aljurf, Mahmoud, Koh, Mickey, Horowitz, Mary M., Ljungman, Per, Weisdorf, Daniel, Saber, Wael, Kodera, Yoshihisa, Szer, Jeff, Jawdat, Dunia, Wood, William A., Brazauskas, Ruta, Lehmann, Leslie, Pasquini, Marcelo C., Seber, Adriana, Lu, Pei Hua, Atsuta, Yoshiko, Riches, Marcie, Perales, Miguel-Angel, Worel, Nina, Okamoto, Shinichiro, Srivastava, Alok, Chemaly, Roy F., Cordonnier, Catherine, Dandoy, Christopher E., Wingard, John R., Kharfan-Dabaja, Mohamed A., Hamadani, Mehdi, Majhail, Navneet S., Waghmare, Alpana A., Chao, Nelson, Kröger, Nicolaus, Shaw, Bronwen, Mohty, Mohamad, Niederwieser, Dietger, Greinix, Hildegard, and Hashmi, Shahrukh K.

Published
2020
Full Text
View/download PDF

15. Pneumocystis pneumonia after allogeneic hematopoietic cell transplantation: A case-control study on epidemiology and risk factors on behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Author

Robin, Christine, primary, Cordonnier, Catherine, additional, Tridello, Gloria, additional, Knelange, Nina, additional, Xhaard, Alienor, additional, Chantepie, Sylvain, additional, Tanguy-Schmidt, Aline, additional, Schouten, Harry C, additional, Yesherun, Moshe, additional, Rocha, Vanderson, additional, Srour, Micha, additional, Kröger, Nicolaus, additional, Ledoux, Marie-Pierre, additional, Dalgaard, Jakob, additional, Thiebaut, Anne, additional, Giardino, Stefano, additional, Calore, Elisabetta, additional, Zuckerman, Tsila, additional, Groll, Andreas H, additional, Raida, Ludek, additional, Avcin, Simona, additional, Vicent, Marta Gonzalez, additional, Kaare, Ain, additional, Drozd-Sokolowska, Joanna, additional, Turlure, Pascal, additional, Bretagne, Stéphane, additional, Mikulska, Malgorzata, additional, Camara, Rafael de la, additional, Cesaro, Simone, additional, and Styczynski, Jan, additional

Published
2023
Full Text
View/download PDF

16. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Author

Garnache-Ottou, Francine, Vidal, Chrystelle, Biichlé, Sabeha, Renosi, Florian, Poret, Eve, Pagadoy, Maïder, Desmarets, Maxime, Roggy, Anne, Seilles, Estelle, Soret, Lou, Schillinger, Françoise, Puyraimond, Sandrine, Petrella, Tony, Preudhomme, Claude, Roumier, Christophe, MacIntyre, Elisabeth A., Harrivel, Véronique, Desbrosses, Yohan, Gruson, Bérengère, Geneviève, Franck, Thepot, Sylvain, Drebit, Yuriy, Leguay, Thibaut, Gros, François-Xavier, Lechevalier, Nicolas, Saussoy, Pascale, Salaun, Véronique, Cornet, Edouard, Benseddik, Zehaira, Veyrat-Masson, Richard, Wagner-Ballon, Orianne, Salanoubat, Célia, Maynadié, Marc, Guy, Julien, Caillot, Denis, Jacob, Marie-Christine, Cahn, Jean-Yves, Gressin, Rémy, Rose, Johann, Quesnel, Bruno, Guerin, Estelle, Trimoreau, Franck, Feuillard, Jean, Gourin, Marie-Pierre, Plesa, Adriana, Baseggio, Lucile, Arnoux, Isabelle, Vey, Norbert, Blaise, Didier, Lacroix, Romaric, Arnoulet, Christine, Benet, Blandine, Dorvaux, Véronique, Bret, Caroline, Drenou, Bernard, Debliquis, Agathe, Latger-Cannard, Véronique, Bonmati, Caroline, Bene, Marie-Christine, Peterlin, Pierre, Ticchioni, Michel, Rohrlich, Pierre-Simon, Arnaud, Anne, Wickenhauser, Stefan, Bardet, Valérie, Brechignac, Sabine, Papoular, Benjamin, Raggueneau, Victoria, Vargaftig, Jacques, Letestu, Rémi, Lusina, Daniel, Braun, Thorsten, Foissaud, Vincent, Tamburini, Jérôme, Bennani, Hind, Freynet, Nicolas, Cordonnier, Catherine, Le Garff-Tavernier, Magali, Jacques, Nathalie, Maloum, Karim, Roos-Weil, Damien, Bouscary, Didier, Asnafi, Vahid, Lhermitte, Ludovic, Suarez, Felipe, Lengline, Etienne, Féger, Frédéric, Battipaglia, Giorgia, Mohty, Mohamad, Bouyer, Sabrina, Ghoual, Ouda, Dindinaud, Elodie, Basle, Caroline, Puyade, Mathieu, Lafon, Carinne, Fest, Thierry, Roussel, Mikael, Cahu, Xavier, Bera, Elsa, Daliphard, Sylvie, Jardin, Fabrice, Campos, Lydia, Solly, Françoise, Guyotat, Denis, Galoisy, Anne-Cécile, Eischen, Alice, Mayeur-Rousse, Caroline, Guffroy, Blandine, Recher, Christian, Loosveld, Marie, Garnier, Alice, Barlogis, Vincent, Rosenthal, Maria Alessandra, Brun, Sophie, Contentin, Nathalie, Maury, Sébastien, Callanan, Mary, Lefebvre, Christine, Maillard, Natacha, Okamba, Patricia, Ferrand, Christophe, Adotevi, Olivier, Saas, Philippe, Angelot-Delettre, Fanny, Binda, Delphine, and Deconinck, Eric

Published
2019
Full Text
View/download PDF

20. Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.

Author

Papanicolaou, Genovefa A, Avery, Robin K, Cordonnier, Catherine, Duarte, Rafael F, Haider, Shariq, Maertens, Johan, Peggs, Karl S, Solano, Carlos, Young, Jo-Anne H, Fournier, Martha, Murray, Rose Ann, Wu, Jingyang, Winston, Drew J, and Investigators, AURORA Trial

Subjects
HEMATOPOIETIC stem cell transplantation, PROTEIN kinase inhibitors, DRUG toxicity, PATIENT safety, DRUG side effects, RESEARCH funding, CYTOMEGALOVIRUS diseases, STATISTICAL sampling, BLIND experiment, TERMINATION of treatment, RANDOMIZED controlled trials, DESCRIPTIVE statistics, SURGICAL complications, VALGANCICLOVIR, DRUG efficacy, RESEARCH, VIREMIA, CONFIDENCE intervals, PATIENT aftercare, NEUTROPENIA
Abstract

Background Neutropenia may limit the use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT). A phase 2 study indicated efficacy of maribavir with fewer treatment-limiting toxicities than valganciclovir. Methods In this multicenter, double-blind, phase 3 study, patients with first asymptomatic CMV infection post-HCT were stratified and randomized 1:1 to maribavir 400 mg twice daily or valganciclovir (dose-adjusted for renal clearance) for 8 weeks with 12 weeks of follow-up. The primary endpoint was confirmed CMV viremia clearance at week 8 (primary hypothesis of noninferiority margin of 7.0%). The key secondary endpoint was a composite of the primary endpoint with no findings of CMV tissue-invasive disease at week 8 through week 16. Treatment-emergent adverse events (TEAEs) were assessed. Results Among patients treated (273 maribavir; 274 valganciclovir), the primary endpoint of noninferiority of maribavir was not met (maribavir, 69.6%; valganciclovir, 77.4%; adjusted difference: −7.7%; 95% confidence interval [CI]: −14.98, −.36; lower limit of 95% CI of treatment difference exceeded −7.0%). At week 16, 52.7% and 48.5% of patients treated (maribavir and valganciclovir, respectively) maintained CMV viremia clearance without tissue-invasive disease (adjusted difference: 4.4%; 95% CI: −3.91, 12.76). With maribavir (vs valganciclovir), fewer patients experienced neutropenia (16.1% and 52.9%) or discontinued due to TEAEs (27.8% and 41.2%). Discontinuations were mostly due to neutropenia (maribavir, 4.0%; valganciclovir, 17.5%). Conclusions Although noninferiority of maribavir to valganciclovir for the primary endpoint was not achieved based on the prespecified noninferiority margin, maribavir demonstrated comparable CMV viremia clearance during post-treatment follow-up, with fewer discontinuations due to neutropenia. Clinical Trials Registration. NCT02927067 [AURORA]. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Remarques sur les recommandations de l'European Conference for Infections in Leukaemia pour la prise en charge de la toxoplasmose en hématologie.

Author

Robin, Christine, Xhaard, Alienor, Bretagne, Stéphane, and Cordonnier, Catherine

Abstract

Copyright of Hematologie is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

23. De-escalation and discontinuation strategies in high-risk neutropenic patients: an interrupted time series analyses of antimicrobial consumption and impact on outcome

Author

la Martire, Giulia, Robin, Christine, Oubaya, Nadia, Lepeule, Raphaël, Beckerich, Florence, Leclerc, Mathieu, Barhoumi, Walid, Toma, Andréa, Pautas, Cécile, Maury, Sébastien, Akrout, Wiem, Cordonnier-Jourdin, Catherine, Fihman, Vincent, Venditti, Mario, and Cordonnier, Catherine

Published
2018
Full Text
View/download PDF

25. Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer

Author

Maertens, Johan, Lodewyck, Tom, Donnelly, J Peter, Chantepie, Sylvain, Robin, Christine, Blijlevens, Nicole, Turlure, Pascal, Selleslag, Dominik, Baron, Frederic, Aoun, Mickael, Heinz, Werner J, Bertz, Hartmut, Racil, Zdenek, Vandercam, Bernard, Drgona, Lubos, Coiteux, Valerie, Llorente, Cristina Castilla, Schaefer-Prokop, Cornelia, Paesmans, Marianne, Ameye, Lieveke, Meert, Liv, Cheung, Kin Jip, Hepler, Deborah A, Loeffler, Juergen, Barnes, Rosemary, Marchetti, Oscar, Verweij, Paul, Lamoth, Frederic, Bochud, Pierre-Yves, Schwarzinger, Michael, and Cordonnier, Catherine

Subjects
Microbiology (medical), empiric, Science & Technology, Immunology, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], FEBRILE, STEM-CELL TRANSPLANTS, Microbiology, THERAPY, PERSISTENT FEVER, preemptive, CIRCULATING GALACTOMANNAN, All institutes and research themes of the Radboud University Medical Center, Infectious Diseases, galactomannan, neutropenia, COMPUTED-TOMOGRAPHY, INVASIVE FUNGAL-INFECTION, LIPOSOMAL AMPHOTERICIN-B, ASPERGILLOSIS, Life Sciences & Biomedicine, HEMATOLOGY PATIENTS, antifungal, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Background Empiric antifungal therapy is considered the standard of care for high-risk neutropenic patients with persistent fever. The impact of a preemptive, diagnostic-driven approach based on galactomannan screening and chest computed tomography scan on demand on survival and on the risk of invasive fungal disease (IFD) during the first weeks of high-risk neutropenia is unknown. Methods Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly assigned to receive caspofungin empirically (arm A) or preemptively (arm B), while receiving fluconazole 400 mg daily prophylactically. The primary end point of this noninferiority study was overall survival (OS) 42 days after randomization. Results Of 556 patients recruited, 549 were eligible: 275 in arm A and 274 in arm B. Eighty percent of the patients had AML or MDS requiring high-dose chemotherapy, and 93% of them were in the first induction phase. At day 42, the OS was not inferior in arm B (96.7%; 95% confidence interval [CI], 93.8%–98.3%) when compared with arm A (93.1%; 95% CI, 89.3%–95.5%). The rates of IFDs at day 84 were not significantly different, 7.7% (95% CI, 4.5%–10.8%) in arm B vs 6.6% (95% CI, 3.6%–9.5%) in arm A. The rate of patients who received caspofungin was significantly lower in arm B (27%) than in arm A (63%; P < .001). Conclusions The preemptive antifungal strategy was safe for high-risk neutropenic patients given fluconazole as prophylaxis, halving the number of patients receiving antifungals without excess mortality or IFDs. Clinical Trials Registration. NCT01288378; EudraCT 2010-020814-27.

Published
2022

26. A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).

Author

Wilck, Marissa, Cornely, Oliver A, Cordonnier, Catherine, Velez, Juan Diego, Ljungman, Per, Maertens, Johan, Selleslag, Dominik, Mullane, Kathleen M, Nabhan, Samir, Chen, Qiuxu, Dagan, Ron, Richmond, Peter, Daus, Caroline, Geddie, Kateasha, Tamms, Gretchen, Sterling, Tina, Patel, Shrita M, Shekar, Tulin, Musey, Luwy, and Buchwald, Ulrike K

Subjects
DRUG tolerance, IMMUNOGLOBULINS, VACCINE immunogenicity, PNEUMOCOCCAL vaccines, PATIENTS, VACCINE effectiveness, TREATMENT effectiveness, COMPARATIVE studies, RANDOMIZED controlled trials, SEROTYPES, BLIND experiment, RESEARCH funding, DESCRIPTIVE statistics, HEMATOPOIETIC stem cell transplantation, STATISTICAL sampling, TRANSPLANTATION of organs, tissues, etc., PATIENT safety
Abstract

Background Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompromised and at high risk of pneumococcal infections, especially in the months following transplant. This study evaluated the safety and immunogenicity of V114 (VAXNEUVANCE; Merck, Sharp & Dohme LLC, a subsidiary of Merck & Co. Inc. Rahway, NJ, USA), a 15-valent pneumococcal conjugate vaccine (PCV), when given to allo-HCT recipients. Methods Participants received 3 doses of V114 or PCV13 (Prevnar 13; Wyeth LLC) in 1-month intervals starting 3–6 months after allo-HCT. Twelve months after HCT, participants received either PNEUMOVAX 23 or a fourth dose of PCV (if they experienced chronic graft vs host disease). Safety was evaluated as the proportion of participants with adverse events (AEs). Immunogenicity was evaluated by measuring serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers (GMTs) for all V114 serotypes in each vaccination group. Results A total of 274 participants were enrolled and vaccinated in the study. The proportions of participants with AEs and serious AEs were generally comparable between intervention groups, and the majority of AEs in both groups were of short duration and mild-to-moderate intensity. For both IgG GMCs and OPA GMTs, V114 was generally comparable to PCV13 for the 13 shared serotypes, and higher for serotypes 22F and 33F at day 90. Conclusions V114 was well tolerated in allo-HCT recipients, with a generally comparable safety profile to PCV13. V114 induced comparable immune responses to PCV13 for the 13 shared serotypes, and was higher for V114 serotypes 22F and 33F. Study results support the use of V114 in allo-HCT recipients. Clinical Trials Registration.  clinicaltrials.gov (NCT03565900) and European Union at EudraCT 2018-000066-11. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial

Author

Cambau, Emmanuelle, Durand-Zaleski, Isabelle, Bretagne, Stéphane, Brun-Buisson, Christian, Cordonnier, Catherine, Duval, Xavier, and Herwegh, Stéphanie

Subjects
Medical care, Cost of -- Economic aspects -- Health aspects -- Analysis -- Usage, Infective endocarditis -- Analysis -- Economic aspects -- Health aspects -- Usage, Drug resistance in microorganisms -- Usage -- Analysis -- Health aspects -- Economic aspects, Infection -- Usage -- Economic aspects -- Health aspects -- Analysis, Clinical trials -- Health aspects -- Usage -- Analysis -- Economic aspects, Labels -- Usage, Pathogenic microorganisms -- Economic aspects -- Analysis -- Health aspects -- Usage, Health care industry
Abstract

Purpose Microbiological diagnosis (MD) of infections remains insufficient. The resulting empirical antimicrobial therapy leads to multidrug resistance and inappropriate treatments. We therefore evaluated the cost-effectiveness of direct molecular detection of pathogens in blood for patients with severe sepsis (SES), febrile neutropenia (FN) and suspected infective endocarditis (SIE). Methods Patients were enrolled in a multicentre, open-label, cluster-randomised crossover trial conducted during two consecutive periods, randomly assigned as control period (CP; standard diagnostic workup) or intervention period (IP; additional testing with LightCycler.sup.®SeptiFast). Multilevel models used to account for clustering were stratified by clinical setting (SES, FN, SIE). Results A total of 1416 patients (907 SES, 440 FN, 69 SIE) were evaluated for the primary endpoint (rate of blood MD). For SES patients, the MD rate was higher during IP than during CP [42.6% (198/465) vs. 28.1% (125/442), odds ratio (OR) 1.89, 95% confidence interval (CI) 1.43-2.50; P < 0.001], with an absolute increase of 14.5% (95% CI 8.4-20.7). A trend towards an association was observed for SIE [35.4% (17/48) vs. 9.5% (2/21); OR 6.22 (0.98-39.6)], but not for FN [32.1% (70/218) vs. 30.2% (67/222), P = 0.66]. Overall, turn-around time was shorter during IP than during CP (22.9 vs. 49.5 h, P < 0.001) and hospital costs were similar (median, mean ± SD: IP [euro]14,826, [euro]18,118 ± 17,775; CP [euro]17,828, [euro]18,653 ± 15,966). Bootstrap analysis of the incremental cost-effectiveness ratio showed weak dominance of intervention in SES patients. Conclusion Addition of molecular detection to standard care improves MD and thus efficiency of healthcare resource usage in patients with SES. ClinicalTrials.gov registration number: NCT00709358., Author(s): Emmanuelle Cambau [sup.1] [sup.2], Isabelle Durand-Zaleski [sup.3] [sup.4], Stéphane Bretagne [sup.5] [sup.6] [sup.7] [sup.8], Christian Brun-Buisson [sup.9], Catherine Cordonnier [sup.10], Xavier Duval [sup.11], Stéphanie Herwegh [sup.12], Julien Pottecher [sup.13], [...]

Published
2017
Full Text
View/download PDF

28. P07 A Phase 3 randomized, double-blind, comparator-controlled study to evaluate safety, tolerability and immunogenicity of V114 pneumococcal vaccine in haematopoietic cell transplant recipients (PNEU-STEM)

Author

Wilck, Marissa, primary, Cornely, Oliver A, additional, Ljungman, Per, additional, Cordonnier, Catherine, additional, Velez, Juan Diego, additional, Dagan, Ron, additional, Richmond, Peter, additional, Chen, Qiuxu, additional, Daus, Caroline, additional, Geddie, Kateasha, additional, Sterling, Tina, additional, Shekar, Tulin, additional, Musey, Luwy, additional, and Buchwald, Ulrike K, additional

Published
2023
Full Text
View/download PDF

29. PCR on Respiratory Tract Specimens of Immunocompromised Patients to Diagnose Pneumocystosis (PcP): A Systematic Review and Meta-Analysis

Author

Brown, Lottie, primary, Rautemaa-Richardson, Riina, additional, Mengoli, Carlo, additional, Alanio, Alexandre, additional, Barnes, Rosemary A., additional, Bretagne, Stephane, additional, Chen, Sharon C-A., additional, Cordonnier, Catherine, additional, Donnelly, Peter J., additional, Heinz, Werner J., additional, Jones, Brian, additional, Klingspor, Lena, additional, Loeffler, Juergen, additional, Rogers, Thomas R., additional, Rowbotham, Eleanor, additional, White, Lewis, additional, and Cruciani, Mario, additional

Published
2023
Full Text
View/download PDF

32. Effect of Graft Source on Unrelated Donor Hemopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia after Reduced-Intensity or Nonmyeloablative Conditioning: A Study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire

Author

Malard, Florent, Milpied, Noel, Blaise, Didier, Chevallier, Patrice, Michallet, Mauricette, Lioure, Bruno, Clément, Laurence, Hicheri, Yosr, Cordonnier, Catherine, Huynh, Anne, Yakoub-Agha, Ibrahim, Peffault de Latour, Regis, and Mohty, Mohamad

Published
2015
Full Text
View/download PDF

33. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia

Author

Bergeron, Anne, primary, Mikulska, Malgorzata, additional, De Greef, Julien, additional, Bondeelle, Louise, additional, Franquet, Tomas, additional, Herrmann, Jean-Louis, additional, Lange, Christoph, additional, Spriet, Isabel, additional, Akova, Murat, additional, Donnelly, J Peter, additional, Maertens, Johan, additional, Maschmeyer, Georg, additional, Rovira, Montserrat, additional, Goletti, Delia, additional, de la Camara, Rafael, additional, Greinix, Hildegard, additional, Slavin, Monica, additional, Hubacek, Petr, additional, Bergeron, Anne, additional, Cordonnier, Catherine, additional, Kanerva, Jukka, additional, Herbrecht, Raoul, additional, Lanternier, Fanny, additional, Robin, Christine, additional, Einsele, Hermann, additional, Lehrnbecher, Thomas, additional, Groll, Andreas, additional, von Lilienfeld-Toal, Marie, additional, Pana, Dorothea, additional, Roilides, Emmanuel, additional, Kassa, Csaba, additional, Averbuch, Diana, additional, Engelhard, Dan, additional, Cesaro, Simone, additional, Pagano, Livio, additional, Castagnola, Elio, additional, Compagno, Francesca, additional, Mesini, Alessio, additional, Donnelly, Peter J, additional, Styczynski, Jan, additional, Botelho de Sousa, Aida, additional, Aljurf, Mahmoud, additional, Navarro, David, additional, Garcia-Vidal, Carol, additional, Ljungman, Per, additional, Paukssen, Karlis, additional, Ammann, Roland, additional, Lamoth, Frédéric, additional, Hirsch, Hans, additional, Ritz, Nicole, additional, Ceesay, Mansour, additional, Warris, Adilia, additional, and Chemaly, Roy, additional

Published
2022
Full Text
View/download PDF

34. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

Author

Avery, Robin K, Alain, Sophie, Alexander, Barbara D, Blumberg, Emily A, Chemaly, Roy F, Cordonnier, Catherine, Duarte, Rafael F, Florescu, Diana F, Kamar, Nassim, Kumar, Deepali, Maertens, Johan, Marty, Francisco M, Papanicolaou, Genovefa A, Silveira, Fernanda P, Witzke, Oliver, Wu, Jingyang, Sundberg, Aimee K, and Fournier, Martha

Subjects
Microbiology (medical), drug resistance, maribavir, transplant recipients, Medizin, virus diseases, Cytomegalovirus, Antiviral Agents, Infectious Diseases, antiviral agents, Cytomegalovirus Infections, Drug Resistance, Viral, Humans, Valganciclovir, Viremia, cytomegalovirus, Ganciclovir, Dichlororibofuranosylbenzimidazole, Foscarnet
Abstract

Background Therapies for refractory cytomegalovirus infections (with or without resistance [R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti-cytomegalovirus activity through the inhibition of UL97 protein kinase. Methods In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomized 2:1 to maribavir 400 mg twice daily or investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for 8 weeks, with 12 weeks of follow-up. The primary endpoint was confirmed cytomegalovirus clearance at end of week 8. The key secondary endpoint was achievement of cytomegalovirus clearance and symptom control at end of week 8, maintained through week 16. Results 352 patients were randomized (235 maribavir; 117 IAT). Significantly more patients in the maribavir versus IAT group achieved the primary endpoint (55.7% vs 23.9%; adjusted difference [95% confidence interval (CI)]: 32.8% [22.80–42.74]; P Conclusions Maribavir was superior to IAT for cytomegalovirus viremia clearance and viremia clearance plus symptom control maintained post-therapy in transplant recipients with R/R cytomegalovirus. Maribavir had fewer treatment discontinuations due to TEAEs than IAT. Clinical Trials Registration. NCT02931539 (SOLSTICE).

Published
2021

35. Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study

Author

3003 Study Group, Cordonnier, Catherine, Ljungman, Per, Juergens, Christine, Maertens, Johan, Selleslag, Dominik, Sundaraiyer, Vani, Giardina, Peter C., Clarke, Keri, Gruber, William C., Scott, Daniel A., and Schmoele-Thoma, Beate

Published
2015

37. Transplant results in adults with Fanconi anaemia

Author

Bierings, Marc, Bonfim, Carmem, Peffault De Latour, Regis, Aljurf, Mahmoud, Mehta, Parinda A., Knol, Cora, Boulad, Farid, Tbakhi, Abdelghani, Esquirol, Albert, McQuaker, Grant, Sucak, Gulsan A., Othman, Tarek B., Halkes, Constantijn J. M., Carpenter, Ben, Niederwieser, Dietger, Zecca, Marco, Kröger, Nicolaus, Michallet, Mauricette, Risitano, Antonio M., Ehninger, Gerhard, Porcher, Raphael, Dufour, Carlo, Bonfirm, Carmem, Socié, Gerard, Gurman, Gunham, Ghavamzadeh, Ardesir, Hamladji, Rise‐Marie, van Lint, M.T., Stepensky, Polina, Koh, Mickey, Ozkurt, Zubeyde Nur, Veelken, Joan Hendrik, Bunjes, Donald, Beelen, Dietrich, Campos, Antonio, Robinson, Stephen, Alessandrino, E. Paolo, Unal, Ali, Fernandez Navarro, José Maria, Mufti, G.J., Velardi, Andrea, Passweg, Jakob, Apperley, Jane, Sengeloev, Henrik, Ljungman, Per, Foá, Roberto, Alegre, Adrián, Espiga, Carlos Richard, Cornelissen, J.J., Di Bartolomeo, Paolo, Cordonnier, Catherine, Browne, Paul, Jubert, Charlotte, Gastl, Günther, Pierelli, Luca, Johansson, Jan‐Erik, Fagioli, Franca, Moraleda, José, Zuckerman, Tsila, Bazarbachi, Ali, Sedlacek, Petr, Rössig, Claudia, Wynn, R.F., Hallek, Michael, Toren, Amos, Zudaire, Teresa, Clausen, Joahannes, Spencer, Andrew, Grazon Lopez, Sebastian, Schots, Rik, Komarnicki, M., González Muniz, Soledad, Vitek, Antonin, Rambaldi, Alessandro, Merli, Francesco, Rubio, Marie Thérese, Rossig, Claudia, Cabrera Marín, José Rafael, Porto, Fulvio, Kerre, Tessa, Metzner, Bernd, Stein, Jerry, Bertrand, Yves, Ciceri, Fabio, Chybicka, Alicja, Diez‐Martin, J.L., Bayoumy, Mohamed, de la Fuente, Josu, and Fegueux, Nathalie

Published
2018
Full Text
View/download PDF

38. Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study

Author

Gratwohl, Alois, Iacobelli, Simona, Bootsman, Natalia, van Biezen, Anja, Baldomero, Helen, Arcese, William, Arnold, Renate, Bron, Dominique, Cordonnier, Catherine, Ernst, Peter, Ferrant, Augustin, Frassoni, Francesco, Gahrton, Gösta, Richard, Carlos, Kolb, Hans Jochem, Link, Hartmut, Niederwieser, Dietger, Ruutu, Tapani, Schattenberg, Anton, Schmitz, Norbert, Torres-Gomez, Antonio, Zwaan, Ferry, Apperley, Jane, Olavarria, Eduardo, Kröger, Nicolaus, and for the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation EBMT

Published
2016
Full Text
View/download PDF

39. When to change treatment of acute invasive aspergillosis: an expert viewpoint

Author

Slavin, Monica A., Chen, Yee-Chun, Cordonnier, Catherine, Cornely, Oliver A., Cuenca-Estrella, Manuel, Donnelly, J. Peter, Groll, Andreas H., Lortholary, Olivier, Marty, Francisco M., Nucci, Marcio, Rex, John H., Rijnders, Bart J. A., Thompson, George R., Verweij, Paul E., White, P. Lewis, Hargreaves, Ruth, Harvey, Emma, Maertens, Johan A., Slavin, Monica A., Chen, Yee-Chun, Cordonnier, Catherine, Cornely, Oliver A., Cuenca-Estrella, Manuel, Donnelly, J. Peter, Groll, Andreas H., Lortholary, Olivier, Marty, Francisco M., Nucci, Marcio, Rex, John H., Rijnders, Bart J. A., Thompson, George R., Verweij, Paul E., White, P. Lewis, Hargreaves, Ruth, Harvey, Emma, and Maertens, Johan A.

Abstract

Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with >= 2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.

Published
2022

40. When to change treatment of acute invasive aspergillosis:an expert viewpoint

Author

Slavin, Monica A., Chen, Yee Chun, Cordonnier, Catherine, Cornely, Oliver A., Cuenca-Estrella, Manuel, Donnelly, J. Peter, Groll, Andreas H., Lortholary, Olivier, Marty, Francisco M., Nucci, Marcio, Rex, John H., Rijnders, Bart J.A., Thompson, George R., Verweij, Paul E., White, P. Lewis, Hargreaves, Ruth, Harvey, Emma, Maertens, Johan A., Slavin, Monica A., Chen, Yee Chun, Cordonnier, Catherine, Cornely, Oliver A., Cuenca-Estrella, Manuel, Donnelly, J. Peter, Groll, Andreas H., Lortholary, Olivier, Marty, Francisco M., Nucci, Marcio, Rex, John H., Rijnders, Bart J.A., Thompson, George R., Verweij, Paul E., White, P. Lewis, Hargreaves, Ruth, Harvey, Emma, and Maertens, Johan A.

Abstract

Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.

Published
2022

41. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling

Author

Locatelli, Franco, Kabbara, Nabil, Ruggeri, Annalisa, Ghavamzadeh, Ardeshir, Roberts, Irene, Li, Chi Kong, Bernaudin, Françoise, Vermylen, Christiane, Dalle, Jean-Hugues, Stein, Jerry, Wynn, Robert, Cordonnier, Catherine, Pinto, Fernando, Angelucci, Emanuele, Socié, Gérard, Gluckman, Eliane, Walters, Mark C., and Rocha, Vanderson

Published
2013
Full Text
View/download PDF

43. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant

Author

Solano, Carlos, Slavin, Monica, Shaul, Alissa J., Marks, David I., Cordonnier, Catherine, Cornely, Oliver A., Pagliuca, Antonio, Cragin, Lael, Jarque, Isidro, GarciaVidal, Carolina, Sorensen, Sonja, Vanness, David J., Charbonneau, Claudie, Barrueta, Jon Andoni, Peral, Carmen, De SalasCansado, Marina, and Bow, Eric J.

Published
2017
Full Text
View/download PDF

44. Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

Author

Thomas, Xavier, Raffoux, Emmanuel, Renneville, Aline, Pautas, Cécile, de Botton, Stéphane, de Revel, Thierry, Reman, Oumedaly, Terré, Christine, Gardin, Claude, Chelghoum, Youcef, Boissel, Nicolas, Quesnel, Bruno, Cordonnier, Catherine, Bourhis, Jean-Henri, Elhamri, Mohamed, Fenaux, Pierre, Preudhomme, Claude, Socié, Gérard, Michallet, Mauricette, Castaigne, Sylvie, and Dombret, Hervé

Published
2012
Full Text
View/download PDF

46. Reply to Stefani et al

Author

Cordonnier, Catherine, Bretagne, Stephane, and Schwarzinger, Michael

Published
2010

47. Reply to Marr et al

Author

Cordonnier, Catherine and Schwarzinger, Michael

Published
2009

50. Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

Author

Segal, Brahm H., Herbrecht, Raoul, Stevens, David A., Ostrosky-Zeichner, Luis, Sobel, Jack, Viscoli, Claudio, Walsh, Thomas J., Maertens, Johan, Patterson, Thomas F., Perfect, John R., Dupont, Bertrand, Wingard, John R., Calandra, Thierry, Kauffman, Carol A., Graybill, John R., Baden, Lindsey R., Pappas, Peter G., Bennett, John E., Kontoyiannis, Dimitrios P., Cordonnier, Catherine, Viviani, Maria Anna, Bille, Jacques, Almyroudis, Nikolaos G., Wheat, L. Joseph, Graninger, Wolfgang, Bow, Eric J., Holland, Steven M., Kullberg, Bart-Jan, Dismukes, William E., and De Pauw, Ben E.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results